ArticleCureus2025
Alcohol-Induced Neuroleptic Malignant Syndrome Complicated by Severe Acute Rhabdomyolysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case highlights a rare instance of alcohol-induced neuroleptic malignant syndrome (NMS) complicated by acute severe rhabdomyolysis, emphasizing the importance of recognizing atypical presentations of NMS. In June 2024, a 22-year-old male presented to the emergency department of a tertiary hospital in Florida with an acute alteration in mental status following alcohol consumption. Physical examination revealed neurological deficits alongside significant vital signs, including a temperature of 38°C, tachycardia, and hypertension. Key laboratory findings included a creatinine phosphokinase (CPK) level exceeding 100,000 U/L, aspartate aminotransferase (AST) above 3,000 U/L, alanine aminotransferase (ALT) above 500 U/L, and a lithium level below 0.20 mmol/L. The patient's medical history of bipolar disorder, managed with lithium, and recent alcohol intake suggest alcohol's role as a trigger for NMS in the context of lithium treatment, compounded by severe rhabdomyolysis. This case underscores the need for heightened clinical awareness of such complex interactions and highlights the critical importance of early recognition and multidisciplinary management to prevent potentially fatal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.